Clinical Trial Update: PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

View source ↗

Summary

This clinicopathologic study investigates PI3K pathway activation markers in estrogen receptor-positive, HER2-negative breast cancer with a PIK3CA gene mutation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Assiut University | Conditions: Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation | Status: NOT_YET_RECRUITING